A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
UMC Utrecht
Pfizer
A2 Biotherapeutics Inc.
Revolution Medicines, Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Colorado, Denver
University of Nebraska
Natera, Inc.
Var2 Pharmaceuticals
Massive Bio, Inc.
Chongqing Precision Biotech Co., Ltd
Washington University School of Medicine
A2 Biotherapeutics Inc.
Guardant Health, Inc.
ModeX Therapeutics, An OPKO Health Company
Shanghai Cingularbio Co. Ltd
Columbia University
University of Arizona
Stanford University
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd